Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...